Comparison of methods for estimating the cost of human immunodeficiency virus-testing interventions

Journal of Public Health Management and Practice

Volumn 18, Issue 3, 2012, Pages 259-267

  Shrestha, Ram K ^a   Sansom, Stephanie L ^a   Farnham, Paul G ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

cost analysis methods; economic evaluation; HIV testing

Indexed keywords

ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; ECONOMICS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAID; PUBLIC HEALTH SERVICE; RESOURCE ALLOCATION; STATISTICS; UNITED STATES;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DIAGNOSTIC TECHNIQUES AND PROCEDURES; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MEDICAID; NEW YORK; RESOURCE ALLOCATION; UNITED STATES;

EID: 84859722316     PISSN: 10784659     EISSN: None     Source Type: Journal    
DOI: 10.1097/PHH.0b013e31822b2077     Document Type: Article

References (48)

1. Lasry A, Sansom SL, Hicks KA, Uzunangelov V. A model for allocating CDC's HIV prevention resources in the United States. Health Care Manag Sci. 2011;14(1):115-124.
2. Centers for Disease Control and Prevention. Number of persons tested for HIV-United States, 2002.MMWRMorb Mortal Wkly Rep. 2004;53(47):1110-1113.
3. Dooley SW Jr, Douglas JM Jr, Janssen RS. Partner counseling and referral services for HIV infection: New endorsement of an old approach. Am J Prev Med. 2007;33(2)(suppl):S81-S83.
4. Centers for Disease Control and Prevention. HIV Counseling and Testing at CDC-Supported Sites-United States, 1999-2004. Atlanta, GA: Centers for Disease Control and Prevention; 2006.
5. Centers for Disease Control and Prevention. Persons tested forHIV-United States, 2006.MMWRMorb Mortal Wkly Rep. 2008;57(31):845-849.
6. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-529.
7. Centers for Disease Control and Prevention. Advancing HIV prevention: New strategies for a changing epidemic-United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(15):329-332.
8. Centers for Disease Control and Prevention. Consultation on Revised Guidelines for HIV Counseling, Testing, and Referral in Non-Health-care Settings. http://www.cdc.gov/hiv/topics/ testing/resources/other/consultation. htm. Accessed September 6, 2011.
9. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Morb Mortal Wkly Rep. 2001;50(RR19):1-58.
10. Brandeau ML, Zaric GS, deAngelis V. Improved allocation of HIV prevention resources: Using information about prevention program production functions. Health Care Manag Sci. 2005;8(1):19-28.
11. Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York, NY: Plenum Press; 1998.
12. Lipscomb J, Barnett PG, Brown ML, Lawrence W, Yabroff KR. Advancing the science of health care costing. Med Care. 2009;47(7):S120-S126.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
14. Toomey KE, Peterman TA, Dicker LW, Zaidi AA, Wroten JE, Carolina J. Human immunodeficiency virus partner notification. Cost and effectiveness data from an attempted randomized controlled trial. Sex Transm Dis. 1998;25(6):310-316.
15. Golden MR, Gift TL, Brewer DD, et al. Peer referral for HIV case-finding among men who have sex with men. AIDS. 2006;20(15):1961-1968.
16. Farnham PG, HutchinsonAB, Sansom SL, Branson BM.Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep. 2008;123(suppl 3):51-62.
17. Frick KD. Microcosting quantity data collection methods. Med Care. 2009;47(7) (suppl 1):S76-S81.
18. Smith MW, Barnett PG. Direct measurement of health care costs. Med Care Res Rev. 2003;60(3):74s-91s.
19. Branson B. Current HIV epidemiology and revised recommendations for HIV testing in health-care settings. J Med Virol. 2007;79(suppl 1):S6-S10.
20. Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006;8(2):125-131.
21. Branson BM. Point-of-care rapid tests for HIV antibodies. J Lab Med. 2003;27(7/8):288-295.
22. Farnham PG, Gorsky RD, Holtgrave DR, Jones WK, Guinan ME.Counseling and testing forHIV prevention: Costs, effects, and cost-effectiveness of more rapid screening tests. Public Health Rep. 1996;111(1):44-53.
23. Shrestha RK, Sansom SL, Kimbrough L, et al. Costeffectiveness of using social networks to identify undiagnosed HIV infection among minority populations. J Public Health Manag Pract. 2010;16(5):457-464.
24. Begley EB, Oster AM, Song B, et al. Incorporating rapid HIV testing into partner counseling and referral services. Public Health Rep. 2008;123(suppl 3):126-135.
25. Kimbrough LW, Fisher HE, Jones KT, Johnson W, Thadiparthi S, Dooley S. Accessing social networks with high rates of undiagnosed HIV infection: The social networks demonstration project. Am J Public Health. 2009;99(6):1093-1099.
26. Schulden JD, Song B, Barros A, et al. Rapid HIV testing in transgender communities by community-based organizations in three cities. Public Health Rep. 2008;123(suppl 3):101-114.
27. Shrestha RK, Begley EB, Hutchinson AB, et al. Costs and effectiveness of partner counseling and referral services with rapid testing for HIV in Colorado and Louisiana, United States. Sex Transm Dis. 2009;36(10):637-641.
28. Shrestha RK, Clark HA, Sansom SL, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123(suppl 3):94-100.
29. Shrestha RK, Sansom SL, Richardson-Moore A, et al. Costs of voluntary rapidHIV testing and counseling in jails in 4 statesadvancingHIV prevention demonstration project, 2003-2006. Sex Transm Dis. 2009;36(2):5-8.
30. Shrestha RK, Sansom SL, Schulden JD, et al. Costs and effectiveness of finding newHIV diagnoses by using rapid testing in transgender communities. AIDS Educ Prev. 2011;23(suppl 3):49-57.
31. Macgowan R,Margolis A, Richardson-Moore A, et al. Voluntary rapid human immunodeficiency virus (HIV) testing in jails. Sex Transm Dis. 2009;36(2) (suppl):S9-S13.
32. DrummondMF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1996.
33. Haddix AC, Teutsch SM, Corso PS. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 2003.
34. Gorsky RD. A method to measure the costs of counseling for HIV prevention. Public Health Rep. 1996;111(suppl 1):115-122.
35. Centers for Disease Control and Prevention. Rapid HIV test distribution-United States, 2003-2005. MMWR Morb Mortal Wkly Rep. 2006;55(24):673-676.
36. Barnett PG. An improved set of standards for finding cost for cost-effectiveness analysis. Med Care. 2009;47(7):S82-S88.
37. Feldman I. New York State Department of Health HIV Primary Care Medicaid Program. Washington, DC: National Association of State Medicaid Directors; 2008.
38. Pavia AT, Benyo M, Niler L, Risk I. Partner notification for control of HIV: Results after 2 years of a statewide program in Utah. Am J Public Health. 1993;83(10):1418-1424.
39. Spencer NE, Hoffman RE, Raevsky CA, Wolf FC, Vernon TM. Partner notification for human immunodeficiency virus infection in Colorado: Results across index case groups and costs. Int J STD AIDS. 1993;4(1):26-32.
40. Ahrens K, Kent CK, Kohn RP, et al. HIV partner notification outcomes for HIV-infected patients by duration of infection, San Francisco, 2004 to 2006. J Acquir Immune Defic Syndr. 2007;46(4):479-484.
41. Folland S, Goodman AC, Stano M. The Economics of Health and Healthcare. New Jersey, NJ: Prentice Hall, Inc.; 1997.
42. Dunlap LJ, Zarkin GA, Cowell AJ. Examining variation in treatment costs: A cost function for outpatient methadone treatment programs. Health Serv Res. 2008;43(3): 931-950.
43. Guinness L, Kumaranayake L, Rajaraman B, et al. Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. Bull World Health Organ. 2005;83(11):880-880.
44. Duffy SQ, Dunlap LJ, Feder M, Zarkin GA. A Hybrid Cost Function for Outpatient Nonmethadone Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2008.
45. Levin HM, McEwan PJ. Cost-Effectiveness Analysis: Methods and Applications. New Delhi, India: SAGE Publications; 2001.
46. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule. Atlanta, Georgia: Department of Health and Human Services; 2010. http://www.cms.gov/ ClinicalLabFeeSched/02-clinlab.asp. Accessed February 8, 2011.
47. Henry SG, Ness RM, Stiles RA, Shintani AK, Dittus RS. A cost analysis of colonoscopy using microcosting and time-and-motion techniques. J Gen Intern Med. 2007;22(10): 1415-1421.
48. Robinson S, Roberts T, Barton P, et al. Healthcare and patient costs of a proactive chlamydia screening programme: The Chlamydia Screening Studies project. Sex Transm Infect. 2007;83(4):276-281.